Shelton-based Intensity Therapeutics has raised $6.6 million in its latest stock sale. Intensity is a late-stage clinical biotechnology company focused on the discovery and development of novel cancer therapies designed to kill tumors and increase immune system recognition of cancers. The company sold some 19.8 million shares of its common stock via an at-the-market (ATM) […]
Shelton-based Intensity Therapeutics has raised $6.6 million in its latest stock sale.
Intensity is a late-stage clinical biotechnology company focused on the discovery and development of novel cancer therapies designed to kill tumors and increase immune system recognition of cancers.
The company sold some 19.8 million shares of its common stock via an at-the-market (ATM) offering at an average price of $0.3323 per share.
ATM is a method where a public company sells its newly issued shares directly into the existing trading market at the prevailing market price, rather than through a traditional underwritten offering.
Intensity says the price per share is more than 10% higher than in its most recent public offering in June of this year.
“The proceeds from these ATM sales strengthen our balance sheet considerably and allow us to continue to advance the clinical trials into the second half of 2026," said Lewis H. Bender, president and CEO of Intensity.
Intensity has completed two clinical studies and enrolled over 200 patients for its most promising drug candidate.
The company says the drug has demonstrated the ability to kill tumors and elicit an adaptive immune response within days of injection.
